in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Aptuit and Aegerion sign API supply agreement
12:25 AM MST | January 9, 2013 | Deepti Ramesh
Aptuit (Greenwich, CT) says it has signed a long-term supply agreement with Aegerion Pharmaceuticals (Cambridge, MA), for commercial quantities of the active pharmaceutical ingredient (API) lomitapide. Lomitapide is Aegerion’s orphan drug that is targeted to the treatment of a rare disease caused by a genetic disorder. The drug received new drug application (NDA) approval in December of 2012 and is expected to be launched commercially this month. Previously, Aptuit scientists had established the chemistry for lomitapide, developed and validated its...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee